Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Nephrostomy | Research

Clinical outcomes of intraluminal Iodine-125 seed strand brachytherapy and percutaneous nephrostomy in patients with ureteral carcinoma

Authors: Yonghua Bi, Dechao Jiao, Jianhao Zhang, Yang Wang, Mengdan Su, Jianzhuang Ren, Xinwei Han

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Background

We aimed to evaluate the safety and efficacy of intraluminal iodine-125 seed strand brachytherapy and percutaneous nephrostomy in patients with ureteral carcinoma.

Methods

From January 2014 to January 2023, 48 patients with ureteral cancer not suitable for surgical resection were enrolled. Iodine-125 seed strand was inserted in 26 patients under c-arm CT and fluoroscopic guidance (Group A), and 22 patients underwent percutaneous nephrostomy without seed strand (Group B). The clinical outcomes (technical success rate, tumor sizes, hydronephrosis Girignon grade, complications, objective response rate (ORR), disease control rate (DCR), and survival time) were evaluated and compared.

Results

A total of 53 seed strands were successfully inserted and replaced in Group A, with a technical success rate of 100%. No procedure-related death or severe complications occurred in both group. Migration of seed strand or drainage tube was the most common complication. The Girignon grade of hydronephrosis was significantly improved 1, 3 and 6 months after procedure in both groups. DCR in Group A were 96.2%, 80.0%, and 70.0% at 1-, 3-, and 6-month follow up, respectively. At 1 and 6 months later, ORR in Group A were significantly higher than those in Group B (p < 0.05). The median overall survival were 30.0 months in Group A and 16.1 months in Group B, respectively (p = 0.04). The median progression-free survival were 11.1 months in Group A and 6.9 months in Group B, respectively (p = 0.09).

Conclusion

Intraluminal Iodine-125 seed strand brachytherapy and percutaneous nephrostomy is safe and effective in patients with ureteral carcinoma, with higher ORR and median overall survival than patients underwent percutaneous nephrostomy without seed strand.
Literature
1.
Ito Y, Kikuchi E, Tanaka N, Miyajima A, Mikami S, Jinzaki M, Oya M. Preoperative hydronephrosis grade independently predicts worse pathological outcomes in patients undergoing nephroureterectomy for upper tract urothelial carcinoma. J Urol. 2011;185(5):1621–6.CrossRefPubMed
2.
Roupret M, Babjuk M, Comperat E, Zigeuner R, Sylvester RJ, Burger M, Cowan NC, Bohle A, Van Rhijn BW, Kaasinen E, et al. European Association of Urology Guidelines on Upper urinary tract Urothelial Cell Carcinoma: 2015 update. Eur Urol. 2015;68(5):868–79.CrossRefPubMed
3.
4.
5.
Li Q, Liang Y, Zhao Y, Gai B. Interpretation of adverse reactions and complications in chinese expert consensus of Iodine-125 brachytherapy for pancreatic cancer. J Cancer Res Ther. 2019;15(4):751–4.CrossRefPubMed
6.
Bi Y, Zhu X, Yu Z, Jiao D, Yi M, Han X, Ren J. Radioactive feeding tube in the palliation of esophageal malignant obstruction. Radiol Med. 2020;125(6):544–50.CrossRefPubMed
7.
Jiao D, Wu G, Ren J, Han X. Study of self-expandable metallic stent placement intraluminal (125)I seed strands brachytherapy of malignant biliary obstruction. Surg Endosc. 2017;31(12):4996–5005.CrossRefPubMed
8.
Zhang ZH, Zhang W, Gu JY, Liu QX, Ma JQ, Liu LX, Wang JH, Luo JJ, Yan ZP. Treatment of Hepatocellular Carcinoma with Tumor Thrombus with the use of Iodine-125 seed strand implantation and Transarterial Chemoembolization: a propensity-score analysis. J Vasc Interv Radiol. 2018;29(8):1085–93.CrossRefPubMed
9.
Campi R, Cotte J, Sessa F, Seisen T, Tellini R, Amparore D, Mormile N, Gobert A, Mari A, Porpiglia F, et al. Robotic radical nephroureterectomy and segmental ureterectomy for upper tract urothelial carcinoma: a multi-institutional experience. World J Urol. 2019;37(11):2303–11.CrossRefPubMed
10.
Hahn AW, Giri S, Pathak R, Bhatt VR, Martin MG. Effect of Adjuvant Radiotherapy on Survival in patients with Locoregional Urothelial Malignancies of the Upper urinary tract. Anticancer Res. 2016;36(8):4051–5.PubMed
11.
Gustin P, Yossi S, Lafont M, Peyraga G, Tremolieres P, Rousseau D, Cellier P, Paumier A, Martin F, Chapet O, et al. [Use of chemotherapy and radiotherapy in the treatment of urothelial carcinoma of the upper urinary tract]. Cancer Radiother. 2015;19(2):120–6.CrossRefPubMed
12.
Maehata Y, Kuriyama K, Aoki S, Araya M, Marino K, Onishi H. Stereotactic Body Radiotherapy for Localized Ureter Transitional Cell Carcinoma: Three Case Reports. Case Rep Urol, 2015; 2015: 519897.
13.
Bui D, Mach KE, Zlatev DV, Rouse RV, Leppert JT, Liao JC. A pilot study of in vivo Confocal Laser Endomicroscopy of Upper Tract Urothelial Carcinoma. J Endourol. 2015;29(12):1418–23.CrossRefPubMedPubMedCentral
14.
Villa L, Cloutier J, Cote JF, Salonia A, Montorsi F, Traxer O. Confocal laser endomicroscopy in the management of endoscopically treated Upper urinary tract Transitional Cell Carcinoma: Preliminary Data. J Endourol. 2016;30(2):237–42.CrossRefPubMed
15.
Bi Y, Li J, Yi M, Yu Z, Han X, Ren J. Self-expanding segmental radioactive metal stents for palliation of malignant esophageal strictures. Acta Radiol, 2019: 284185119886315.
16.
Hu X, Pang Q, Liu H, Qian Z, Jin H, Zhou L, Wang Y, Man Z, Li Z, Yang S. Inflammation-based prognostic scores in patients with extrahepatic bile duct lesions treated by percutaneous transhepatic biliary stenting combined with (125)I seeds intracavitary irradiation. Clin Transl Oncol. 2019;21(5):665–73.CrossRefPubMed
17.
Jiao D, Zhou X, Li Z, Bi Y, Zhang Q, Li J, Li L, Ren J, Han X. A newly designed biliary brachytherapy drainage catheter for patients with malignant biliary obstruction: a pilot study. J Cancer Res Ther. 2020;16(2):286–91.CrossRefPubMed
18.
Wu YF, Wang T, Yue ZD, Zhao HW, Wang L, Fan ZH, He FL, Liu FQ. Stents combined with iodine-125 implantation to treat main portal vein tumor thrombus. World J Gastrointest Oncol. 2018;10(12):496–504.CrossRefPubMedPubMedCentral
19.
Jiao D, Yao Y, Xu K, Lei Q, Li Z, Han X, Ren J. Investigation of a novel brachytherapy ureteral stent: trial studies on normal beagle dogs. J Cancer Res Clin Oncol. 2021;147(4):1115–23.CrossRefPubMed
20.
Zhang W, Luo J, Liu Q, Ma J, Qu X, Yang M, Yan Z, Wang J. Brachytherapy with Iodine-125 seeds strand for treatment of main portal vein tumor thrombi: an experimental study in a rabbit model. Am J Cancer Res. 2016;6(3):587–99.PubMedPubMedCentral
21.
Jiao L, Zhang T, Wang H, Zhang W, Fan S, Huo X, Zheng B, Ma W. Implanting iodine-125 seeds into rat dorsal root ganglion for neuropathic pain: neuronal microdamage without impacting hind limb motion. Neural Regen Res. 2014;9(12):1204–9.CrossRefPubMedPubMedCentral
22.
Wang Y, Guo JH, Zhu GY, Zhu HD, Chen L, Lu J, Wang C, Teng GJ. A Novel Self-Expandable, Radioactive Airway Stent loaded with (125)I Seeds: a feasibility and safety study in healthy Beagle Dog. Cardiovasc Intervent Radiol. 2017;40(7):1086–93.CrossRefPubMed
Metadata
Title
Clinical outcomes of intraluminal Iodine-125 seed strand brachytherapy and percutaneous nephrostomy in patients with ureteral carcinoma
Authors
Yonghua Bi
Dechao Jiao
Jianhao Zhang
Yang Wang
Mengdan Su
Jianzhuang Ren
Xinwei Han
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-10921-3

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue

Research

Effect of asciminib and vitamin K2 on Abelson tyrosine-kinase-inhibitor-resistant chronic myelogenous leukemia cells

Research

Detection of Human cytomegalovirus UL55 Gene and IE/E Protein Expression in Colorectal Cancer Patients in Egypt

Research

Construction and verification of a novel circadian clock related long non-coding RNA model and prediction of treatment for survival prognosis in patients with hepatocellular carcinoma

Research

Efficacy and safety of PD-1 inhibitors in recurrent or metastatic nasopharyngeal carcinoma patients after failure of platinum-containing regimens: a systematic review and meta-analysis

Research

A cisplatin conjugate with tumor cell specificity exhibits antitumor effects in renal cancer models

Research

Clinical outcomes in patients with solid tumors living in rural and urban areas followed via telemedicine: experience in a highly complex latin american hospital

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits